tiprankstipranks
pc:vyria

Vyriad Inc

Vyriad, Inc. is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company leverages engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells, advancing programs in oncolytic virotherapy, in vivo gene therapy, and gene-editing with partnerships including Regeneron and Novartis.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$85M
Total Amount Raised$85M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$85M
Latest Funding Amount$85M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Dec 23, 2025
Series B
$85.00M

Investors

Investor Name
Funding Round

Related News and Analysis